Cas No.: | 75629-57-1 |
Chemical Name: | 1-(4-Chlorobenzyl)-1H-indole-3-carbaldehyde |
Synonyms: | 1-(4-Chlorobenzyl)-1H-indole-3-carbaldehyde;Oncrasin 1;1-[(4-chlorophenyl)methyl]indole-3-carbaldehyde;1-[(4-Chlorophenyl)methyl]-1H-indole-3-carboxaldehyde;1-(4-Chlorobenzyl)-1H-indole-3-carboxaldehyde;Oncrasin-1;1-(4-Chloro-benzyl)-1H-indole-3-carbaldehyde;Oncrasin1;Cambridge id 5601604;N-4-chlorobenzyl-3-formylindole;ZDRQMXCSSAPUMM-UHFFFAOYSA-N;HMS3677L20;HMS3413L20;ALB |
SMILES: | ClC1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N1C([H])=C(C([H])=O)C2=C([H])C([H])=C([H])C([H])=C12 |
Formula: | C16H12ClNO |
M.Wt: | 269.7256 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Oncrasin 1 is a proapoptotic substance. Induces abnormal nuclear aggregation of PKCι and suppressing RNA transcription. Displays antiproliferative effects against various human tumor cell lines. Shown to inhibit human xenograft growth by 75% in vivo. For the detailed information of Oncrasin 1, the solubility of Oncrasin 1 in water, the solubility of Oncrasin 1 in DMSO, the solubility of Oncrasin 1 in PBS buffer, the animal experiment (test) of Oncrasin 1, the cell expriment (test) of Oncrasin 1, the in vivo, in vitro and clinical trial test of Oncrasin 1, the EC50, IC50,and affinity,of Oncrasin 1, For the detailed information of Oncrasin 1, the solubility of Oncrasin 1 in water, the solubility of Oncrasin 1 in DMSO, the solubility of Oncrasin 1 in PBS buffer, the animal experiment (test) of Oncrasin 1, the cell expriment (test) of Oncrasin 1, the in vivo, in vitro and clinical trial test of Oncrasin 1, the EC50, IC50,and affinity,of Oncrasin 1, Please contact DC Chemicals. |
References: | [1]. Guo W, et al. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res. 2008 Sep 15;68(18):7403-8. [2]. Guo W, et al. Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Mol Cancer Ther. 2009 Feb;8(2):441-8. |